Physician profile
Amanda Turner
NPI 1720216021
$7,952.60
in general payments reported to CMS, 2019-2025
54 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,951 · 2022: $1,219 · 2023: $1,669 · 2024: $1,485 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,599.86 | 2021-2025 | |
| Pfizer INC. | $649.58 | 2021-2025 | |
| Lilly USA, LLC | $591.20 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Astrazeneca Pharmaceuticals LP | $471.91 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $368.75 | 2021-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $261.10 | 2021-2024 | Xarelto, Spravato |
| Biohaven Pharmaceuticals, INC. | $244.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $209.15 | 2021-2025 | Austedo Xr, Austedo Xr |
| Aimmune Therapeutics, INC. | $204.13 | 2024-2025 | Zenpep |
| Amgen INC. | $197.15 | 2021-2025 | Evenity, Repatha, Prolia |
| Lundbeck LLC | $197.00 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.95 | 2021-2025 | Synjardy, Jardiance, Tradjenta |
| Boston Scientific Corporation | $184.01 | 2021-2025 | General - Pain Management, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $174.17 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $166.76 | 2023-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.